Tg Therapeutics (TGTX) | Stock Overview & Key Data
Tg Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $27.91
High: $28.88
on August 21, 2025
52 Week Range
Low: $21.11
High: $46.48
on September 6, 2024
on May 1, 2025
All-Time High: $233.44 on May 3, 2010
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$4.4B
EPS
0.38
P/E Ratio (TTM)
73.47
Forward P/E
28.78
P/B Ratio
14.67
PEG Ratio
0.26
Div. Yield
N/A
ROE
26.63%
Beta
1.948
Debt to Equity
92.08
Financial Highlights
Profitability
Gross Margin
86.58%
Operating Margin
24.69%
Profit Margin
13.32%
Returns and Earnings
Return on Assets (TTM)
9.72%
Return on Equity (TTM)
26.63%
EBITDA
$97.7M
Net Income (TTM)
$60.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$2.91
Quarterly Revenue Growth (YoY)
92.10%
Quarterly Earnings Growth (YoY)
309.80%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Tg Therapeutics TGTX | 4.43B Mid-cap | 3.60% | -23.12% | -15.88% | -6.83% | -7.37% | 17.62% | 325.59% | 17.43% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| BridgeBio Pharma BBIO | 9.39B Mid-cap | -1.86% | 9.43% | 52.95% | 36.31% | 78.12% | 98.46% | 379.29% | 69.75% |
| Madrigal MDGL | 8.46B Mid-cap | 9.62% | 23.01% | 46.84% | 21.07% | 29.74% | 61.07% | 481.06% | 281.74% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
9.74%
Institutional Ownership
64.75%
Shares Short
23M
Short Ratio
15.23
Short % of Shares Outstanding
19.43%
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Tg Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Tg Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TGTX's 52-week high and low?
- In the last 52 weeks, Tg Therapeutics reached a high of $46.48 (on May 1, 2025) and a low of $21.11 (on September 6, 2024).
- What is the market cap and P/E ratio for TGTX?
- Curious about Tg Therapeutics's size and valuation? Its market capitalization stands at 4.43B. When it comes to valuation, the P/E ratio (trailing twelve months) is 73.47, and the forward P/E (looking ahead) is 28.78.
- Does TGTX pay dividends? If so, what's the yield?
- As for dividends, Tg Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Tg Therapeutics's main competitors or similar companies to consider before investing?
When looking at Tg Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% BridgeBio Pharma
BBIO9.39B Healthcare Biotechnology 98.46% 379.29% Madrigal
MDGL8.46B Healthcare Biotechnology 61.07% 481.06% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Tg Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Tg Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 26.63%, the Debt to Equity ratio from the most recent quarter is 92.08, and its Gross Profit Margin stands at 86.58%.
- What is the recent revenue and earnings growth for TGTX?
- Looking at Tg Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $454M. Compared to the same quarter last year (YoY), quarterly revenue grew by 92.10%, and quarterly earnings saw a YoY growth of 309.80%.
- How much of TGTX stock is held by insiders and institutions?
- Wondering who owns Tg Therapeutics stock? Company insiders (like executives and directors) hold about 9.74% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 64.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.